High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia

Sergej N. Konoplev; Herbert A. Fritsche; Susan O'Brien; William G. Wierda; Michael J. Keating; Terrie G. Gornet; Susan St Romain; Xuemei Wang; Kedar Inamdar; Malisha R. Johnson; L. Jeffrey Medeiros; Carlos E. Bueso-Ramos

doi:10.1309/AJCPHMYT93HUIZKW

High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia

Sergej N. Konoplev, Herbert A. Fritsche, Susan O'Brien, William G. Wierda, Michael J. Keating, Terrie G. Gornet, Susan St Romain, Xuemei Wang, Kedar Inamdar, Malisha R. Johnson, L. Jeffrey Medeiros, Carlos E. Bueso-Ramos

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Serum thymidine kinase 1 (TK1) levels have been reported to have prognostic significance in patients with chronic lymphocytic leukemia (CLL). Until recently, serum TK1 levels were assessed using inconvenient radioenzyme assays. In this study, we used a novel chemiluminescence assay to assess serum TK1 levels in patients with CLL at the time of first examination. We show that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes, CD38 and ZAP-70 expression, and subsequent risk of developing large B-cell lymphoma (Richter syndrome). Similar findings were observed in a subset of patients treated with current fludarabine-based chemotherapy regimens. We suggest that serum TK1 levels analyzed using this convenient chemiluminescence assay may be useful in the risk assessment of patients with CLL.

Original language	English (US)
Pages (from-to)	472-477
Number of pages	6
Journal	American journal of clinical pathology
Volume	134
Issue number	3
DOIs	https://doi.org/10.1309/AJCPHMYT93HUIZKW
State	Published - Sep 2010

Keywords

Chronic lymphocytic leukemia
Prognostic factors
Serum thymidine kinase 1

ASJC Scopus subject areas

Pathology and Forensic Medicine

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.1309/AJCPHMYT93HUIZKW

Cite this

Konoplev, S. N., Fritsche, H. A., O'Brien, S., Wierda, W. G., Keating, M. J., Gornet, T. G., St Romain, S., Wang, X., Inamdar, K., Johnson, M. R., Jeffrey Medeiros, L., & Bueso-Ramos, C. E. (2010). High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. American journal of clinical pathology, 134(3), 472-477. https://doi.org/10.1309/AJCPHMYT93HUIZKW

Konoplev, SN, Fritsche, HA, O'Brien, S, Wierda, WG, Keating, MJ, Gornet, TG, St Romain, S, Wang, X, Inamdar, K, Johnson, MR, Jeffrey Medeiros, L & Bueso-Ramos, CE 2010, 'High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia', American journal of clinical pathology, vol. 134, no. 3, pp. 472-477. https://doi.org/10.1309/AJCPHMYT93HUIZKW

@article{e786fa2365b3475e977c00ff8b3897e6,

title = "High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia",

abstract = "Serum thymidine kinase 1 (TK1) levels have been reported to have prognostic significance in patients with chronic lymphocytic leukemia (CLL). Until recently, serum TK1 levels were assessed using inconvenient radioenzyme assays. In this study, we used a novel chemiluminescence assay to assess serum TK1 levels in patients with CLL at the time of first examination. We show that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes, CD38 and ZAP-70 expression, and subsequent risk of developing large B-cell lymphoma (Richter syndrome). Similar findings were observed in a subset of patients treated with current fludarabine-based chemotherapy regimens. We suggest that serum TK1 levels analyzed using this convenient chemiluminescence assay may be useful in the risk assessment of patients with CLL.",

keywords = "Chronic lymphocytic leukemia, Prognostic factors, Serum thymidine kinase 1",

author = "Konoplev, {Sergej N.} and Fritsche, {Herbert A.} and Susan O'Brien and Wierda, {William G.} and Keating, {Michael J.} and Gornet, {Terrie G.} and {St Romain}, Susan and Xuemei Wang and Kedar Inamdar and Johnson, {Malisha R.} and {Jeffrey Medeiros}, L. and Bueso-Ramos, {Carlos E.}",

year = "2010",

month = sep,

doi = "10.1309/AJCPHMYT93HUIZKW",

language = "English (US)",

volume = "134",

pages = "472--477",

journal = "American journal of clinical pathology",

issn = "0002-9173",

publisher = "American Society of Clinical Pathologists",

number = "3",

}

TY - JOUR

T1 - High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia

AU - Konoplev, Sergej N.

AU - Fritsche, Herbert A.

AU - O'Brien, Susan

AU - Wierda, William G.

AU - Keating, Michael J.

AU - Gornet, Terrie G.

AU - St Romain, Susan

AU - Wang, Xuemei

AU - Inamdar, Kedar

AU - Johnson, Malisha R.

AU - Jeffrey Medeiros, L.

AU - Bueso-Ramos, Carlos E.

PY - 2010/9

Y1 - 2010/9

N2 - Serum thymidine kinase 1 (TK1) levels have been reported to have prognostic significance in patients with chronic lymphocytic leukemia (CLL). Until recently, serum TK1 levels were assessed using inconvenient radioenzyme assays. In this study, we used a novel chemiluminescence assay to assess serum TK1 levels in patients with CLL at the time of first examination. We show that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes, CD38 and ZAP-70 expression, and subsequent risk of developing large B-cell lymphoma (Richter syndrome). Similar findings were observed in a subset of patients treated with current fludarabine-based chemotherapy regimens. We suggest that serum TK1 levels analyzed using this convenient chemiluminescence assay may be useful in the risk assessment of patients with CLL.

AB - Serum thymidine kinase 1 (TK1) levels have been reported to have prognostic significance in patients with chronic lymphocytic leukemia (CLL). Until recently, serum TK1 levels were assessed using inconvenient radioenzyme assays. In this study, we used a novel chemiluminescence assay to assess serum TK1 levels in patients with CLL at the time of first examination. We show that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes, CD38 and ZAP-70 expression, and subsequent risk of developing large B-cell lymphoma (Richter syndrome). Similar findings were observed in a subset of patients treated with current fludarabine-based chemotherapy regimens. We suggest that serum TK1 levels analyzed using this convenient chemiluminescence assay may be useful in the risk assessment of patients with CLL.

KW - Chronic lymphocytic leukemia

KW - Prognostic factors

KW - Serum thymidine kinase 1

UR - http://www.scopus.com/inward/record.url?scp=77956603870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956603870&partnerID=8YFLogxK

U2 - 10.1309/AJCPHMYT93HUIZKW

DO - 10.1309/AJCPHMYT93HUIZKW

M3 - Article

C2 - 20716805

AN - SCOPUS:77956603870

SN - 0002-9173

VL - 134

SP - 472

EP - 477

JO - American journal of clinical pathology

JF - American journal of clinical pathology

IS - 3

ER -

High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this